Affimed

October 10, 2019

UCB goes to Ra for a complementary approach

The $2bn takeout of Ra Pharmaceuticals provides solace for investors bemoaning the biotech market’s poor performance.

Affimed turns its back on T-cell recruitment

The German group’s decision to switch focus to innate immunity had been on the cards since a deal with Roche last August.

December 10, 2018

Macrogenics’ safety scare could be contagious

It could be hard for Macrogenics to shake off new safety concerns, whether it is the DART bispecific construct or its protein target that is to blame.

December 14, 2017

Ash 2017 winners and losers – Déjà vu

September 01, 2017

Macrogenics and J&J fallout could spell double trouble

March 03, 2017

AACR – Rags to riches to rags again

March 03, 2017

AACR – Rags to riches to rags again

September 02, 2016

Behold the son of Blincyto

February 03, 2016

No safe haven as January crash wipes $644bn off biopharma

January 12, 2016

Deal flurry comes just in time for JP Morgan

December 10, 2015

Winners and losers – An ASH bloodbath

Load More